R&D News | pharmaphorum

News

14/10/2022. London, United Kingdom. Prime Liz Truss appoints Jeremy Hunt as Chancellor. Official portrait of the Chancellor of the Exchequer Jeremy Hunt. Picture by Andrew Parsons / No 10 Downing Street

Industry body slams UK chancellor's R&D tax credits plan for...

A proposal in UK chancellor Jeremy Hunt's autumn statement to overhaul the R&D tax credits system – for small and medium-sized enterprises (SMEs) to reduce what he described as "abuse a

News

Astellas nabs lead in claudin 18.2 after positive stomach ca...

Astellas Pharma's zolbetuximab – currently leading an expanding pack of drugs targeting claudin 18.2 – has shown efficacy in the first of a pair of phase 3 trials of gastric or gastroesopha

News

ImmunoGen ELAHERE wins accelerated FDA approval for ovarian ...

ImmunoGen, Inc.

Views & Analysis

Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results...

Last month, pharmaphorum spoke with Dr Charles C.

News

As resistant tuberculosis rises, GSK says trial backs novel ...

With cases of drug-resistant tuberculosis on the rise again around the world, GSK has sparked hopes of a new treatment option after reporting phase 2a data with a novel antitubercular drug

News

Lantheus on POINT in radio-oncology with $2bn licensing deal

Lantheus' pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma.

Industry body slams UK chancellor's R&D tax credits plan for...

Astellas nabs lead in claudin 18.2 after positive stomach ca...

ImmunoGen ELAHERE wins accelerated FDA approval for ovarian ...

Hope in sight with Apellis’ pegcetacoplan OAKS/DERBY results...

As resistant tuberculosis rises, GSK says trial backs novel ...

Lantheus on POINT in radio-oncology with $2bn licensing deal

FDA's ODAC delivers one loss, one win for AstraZeneca

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks